<DOC>
	<DOCNO>NCT00212836</DOCNO>
	<brief_summary>Treatment conventional antipsychotic haloperidol little effect may sometimes even worsen negative symptom ( blunt affect , emotional withdrawal , poor rapport ) schizophrenia . The new `` atypical '' antipsychotic agent , olanzapine , show improvement treatment negative symptom acute trial . The purpose study compare investigational compound ( asenapine ) market agent ( olanzapine ) treatment stable subject persistent negative symptom schizophrenia 6 month . Patients complete study may eligible participate extension 6 month treatment . Patients require stable symptom prior entry study .</brief_summary>
	<brief_title>Efficacy Safety Asenapine Compared With Olanzapine Patients With Persistent Negative Symptoms Schizophrenia ( 25543 ) ( COMPLETED ) ( P05817 )</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Asenapine</mesh_term>
	<mesh_term>Olanzapine</mesh_term>
	<criteria>Have document current diagnosis schizophrenia paranoid , disorganize , catatonic , residual , undifferentiated subtype persistent negative symptom . No increase level psychiatric care past month due worsen symptom schizophrenia . Caregiver require . Have uncontrolled , unstable clinically significant medical condition . Have psychiatric disorder schizophrenia primary diagnosis include depression .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>